English
 

Dan Zabrowski, Ph.D.
Venture Partner

Dr. Dan Zabrowski is a Venture Partner at Decheng Capital and has been with the firm since July 2016. He is currently serving on the boards of AccuraGen, Apexigen, Ariagen, Encodia, Omniome and ReadCoor.

Prior to joining Decheng, Dr. Zabrowski worked over 20 years for Roche in a number of key global leadership positions, including Global Head of Regulatory Affairs, Global Head of Development Operations, Global Head of Roche Pharma Partnering, President of Ventana Medical Systems and President of the Roche Sequencing Unit. During his tenure in Business Development and Diagnostics, Dr. Zabrowski and his teams delivered 300+ acquisition and partnership deals. In addition, he was Board member of Chugai Pharmaceuticals. Prior to joining Roche, Dr. Zabrowski worked at Syntex, Fujisawa (now Astellas) and G.D. Searle in their pharmaceutical R&D organizations and served as Adjunct Assistant Professor at the School of Pharmacy, University of Illinois — Chicago. Dr. Zabrowski received his PhD in Organic Chemistry from Indiana University, Bloomington and his BA degree in Chemistry from Saint Louis University.

 

 

Min Cui, Ph.D.
Managing Director
Victor E. Tong, Jr.
Partner
Qiang Xu, Ph.D.
Partner
Wei Xu
Partner
Nick Pliam, M.D., Ph.D.
Principal
Tony Tong, Ph.D.
Principal
Peter Colabuono
Principal
Dan Zabrowski, Ph.D.
Venture Partner

Claire Chin, M.D., MBA
Associate

Aaron Li, MBA
Associate
   
Copyright © 2011 Decheng Capital LLC. All Rights Reserved.